AIM
KDNY

Acrospire Investment Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Acrospire Investment Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,940
Closed -$110K – 2214
2016
Q2 		$110K Buy
1,940
+420
+28% +$25.5K 0.08% 371
2016
Q1 		$97K Buy
+1,520
New +$123K 0.07% 342

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acrospire Investment Management's KDNY Position: Q3 2016 in Review

Acrospire Investment Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2016, closing a stake of 1,940 shares — an estimated $110K sold.

Acrospire Investment Management first reported a position in KDNY in Q1 2016 and held it in 2 quarters. The position peaked at $110K in Q2 2016. 92 funds tracked by Wall St. Rank hold KDNY as of Q3 2016.

  • Acrospire Investment Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 1,940 Chinook Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $110K.
  • Acrospire Investment Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Chinook Therapeutics, Inc. Common Stock position peaked at $110K in Q2 2016.
  • 92 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Acrospire Investment Management's 13F filing for Q3 2016, filed 10 Nov 2016.